Liberum hikes target price for GSK but stays at hold
4th Nov 2019 15:50
(Sharecast News) - Analysts at Liberum hiked their target price for shares of GlaxoSmithKline after switching valuation methods given the company's medium-term plans to split its Consumer Health business from its Pharmaceuticals arm.
Read moreGlaxoSmithKline posts better-than-expected Q3 EPS, guides higher for the year
30th Oct 2019 15:59
(Sharecast News) - GlaxoSmithKline shares advanced on Wednesday following the group's better-than-expected third quarter results and upwardly revised financial guidance for the year.
Read moreWednesday preview: Vote in Parliament, GlaxoSmithKline in focus
29th Oct 2019 15:24
(Sharecast News) - The market spotlight on Wednesday will continue to be very much on Brexit, with investors keen to find out what Parliament voted the night before regarding the timing of the upcoming general elections.
Read moreGlaxoSmithKline offloads two travel vaccines to Bavarian Nordic
21st Oct 2019 08:10
(Sharecast News) - GlaxoSmithKline announced the divestment of travel vaccines 'Rabipur', known as Rabavert in the US and used for the prevention of rabies, and 'Encepur' for the prevention of tick-borne encephalitis, to Bavarian Nordic on Monday.
Read moreTuesday broker round-up
3rd Sep 2019 12:59
(Sharecast News) - easyJet: Kepler Cheuvreux downgrades to reduce with a target price of 820p.
Read moreMonday broker round-up
2nd Sep 2019 13:16
(Sharecast News) - Beazley: UBS upgrades to buy with a target price of 650p.
Read moreGlaxoSmithKline reveals positive results from belantamab mafodotin trial
23rd Aug 2019 07:29
(Sharecast News) - GlaxoSmithKline announced positive headline results from the pivotal 'DREAMM-2' open-label, randomised study of two doses of belantamab mafodotin on Friday.
Read moreGlaxoSmithKline upbeat on latest test results from ViiV Healthcare
22nd Aug 2019 07:29
(Sharecast News) - GlaxoSmithKline reported on Thursday that its specialist HIV company ViiV Healthcare had announced positive headline results from its phase 3 'ATLAS-2M' study of the investigational, long-acting, injectable, two-drug regimen (2DR) of its cabotegravir and Janssen's rilpivirine for the treatment of HIV.
Read moreGlaxoSmithKline seeking marketing approval for 'daprodustat' in Japan
21st Aug 2019 08:07
(Sharecast News) - GlaxoSmithKline announced the submission of a Japanese New Drug Application (JNDA) to the Ministry of Health, Labour and Welfare on Wednesday, seeking marketing approval for 'daprodustat'.
Read moreGlaxoSmithKline's Zejula application accepted by US Food and drug administration
24th Jun 2019 13:18
(Sharecast News) - GlaxoSmithKline (GSK) confirmed on Monday Tesaro, its oncology-focused business, submitted a supplemental new drug application to the US Food & Drug Administration for its Zejula cancer treatment.
Read moreMonday broker round-up
17th Jun 2019 12:21
(Sharecast News) - Hammerson: Peel Hunt upgrades to add with a target price of 350p.
Read moreGSK to update on potential cancer treatment at European congress
12th Jun 2019 12:34
(Sharecast News) - GlaxoSmithKline is to present studies on a potential breakthrough cancer treatment at a major conference, the drugs giant confirmed on Wednesday.
Read moreUS approves self administration for GlaxoSmithKline asthma drug
7th Jun 2019 07:15
(Sharecast News) - GlaxoSmithKline said on Friday that US regulators had approved two new methods for self-administering its Nucala asthma treatment.
Read moreGlaxoSmithKline Q1 revenues boosted by shingles vaccine
1st May 2019 12:31
(Sharecast News) - GlaxoSmithKline posted a rise in first-quarter sales on Wednesday as its vaccines division benefited from strong US sales of shingles vaccine Shingrix.
Read moreWednesday broker round-up
24th Apr 2019 12:44
(Sharecast News) - Saga: JP Morgan upgrades to neutral with a target price of 80p.
Read more